Brian Mussio, DO
Nephrology · Columbus, OHNPI 1417146796
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,303 of the $1,853 with a category attached, or 70.3%. CSL Behring accounts for 76.5% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2024 at $1,435 and has fallen 97.5% since, to $37 in 2025.
Across 31 payments — averaging $59.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$1K
- Fresenius USA Marketing, Inc.$137
- Boehringer Ingelheim$123
- Bard Peripheral Vascular, Inc.$86
- Travere Therapeutics, Inc.$35
- AstraZeneca$23
- plus $31 from 2 others
Across 93 payments — averaging $1065.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akebia Therapeutics Inc$70K
- CSL Behring$26K
- AstraZeneca$3K
What the payments were for
- Travel & lodging$1,30370%
- Food & beverage$51528%
- Education$352%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 7 | $1,417 |
| Fresenius USA Marketing, Inc. | 7 | $137 |
| Boehringer Ingelheim | 1 | $123 |
| Bard Peripheral Vascular, Inc. | 1 | $86 |
| Travere Therapeutics, Inc. | 12 | $35 |
| AstraZeneca | 1 | $23 |
| Novo Nordisk | 1 | $19 |
| Amgen | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- JARDIANCE$123
How this compares
$1,853 in reported general payments places this provider in the 60th percentile of 450 nephrology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VelphoroSucroferric Oxyhydroxide | 26 | $60,736 |
| FarxigaDapagliflozin Propanediol | 17 | $20,990 |
| Sevelamer Carbonate | 68 | $17,910 |
| JardianceEmpagliflozin | 11 | $8,509 |
| Clonidine | 13 | $1,188 |
| Potassium Citrate ErPotassium Citrate | 16 | $1,054 |
| Losartan Potassium | 80 | $716 |
| Nifedipine ErNifedipine | 22 | $705 |
| Carvedilol | 70 | $649 |
| Hydralazine Hcl | 31 | $573 |
| Furosemide | 127 | $562 |
| Amlodipine Besylate | 102 | $387 |
| Spironolactone | 45 | $380 |
| Metoprolol Succinate | 38 | $378 |
| Atorvastatin Calcium | 40 | $298 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Fresenius USA Marketing, Inc.Velphoro | $137 | $60,73626 claims |
| AstraZenecaFarxiga | $23 | $20,99017 claims |
| Boehringer IngelheimJardiance | $123 | $8,50911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 450 nephrology providers in Ohio.
Other nephrology in Columbus
- Brad RovinColumbus$379K
- Samir ParikhColumbus$145K
- Isabelle AyoubColumbus$116K
- Anil AgarwalColumbus$99K
- Karim AttiaColumbus$43K
- Rima KangColumbus$28K
- Salem AlmaaniColumbus$21K
- Todd PesaventoColumbus$20K
- Naveen SingriColumbus$11K
- Jessica GrecoColumbus$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.